Mineralys Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2022 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Mineralys Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2022 to 2023.
  • Mineralys Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$60.1M, a 129% decline year-over-year.
  • Mineralys Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$168M, a 151% decline year-over-year.
  • Mineralys Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$84.7M, a 169% decline from 2022.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$84.7M -$53.2M -169% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-21
2022 -$31.5M Jan 1, 2022 Dec 31, 2022 10-K 2024-03-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.